---
schema_version: "secwatch.filing_event.v1"
accession: "0001650664-24-000006"
form_type: "8-K"
ticker: "EDIT"
cik: "0001650664"
company_name: "Editas Medicine, Inc."
filed_at: "2024-02-28T23:59:59+00:00"
generated_at: "2026-06-05T08:59:39.781148+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Editas reports Q4 net loss of $18.9M; Vertex license deal provides cash runway into 2026

## Summary
- Q4 net loss $18.9M ($0.23 per share) vs $60.7M ($0.88) in Q4 2022; revenue boosted by Vertex license.
- Cash $427.1M as of Dec 31, 2023; with Vertex license payments, runway expected into 2026.
- FDA aligns that RUBY trial is single Phase 1/2/3 to support BLA; adolescent cohort enrollment initiated.
- Entered license agreement with Vertex for Cas9 for ex vivo SCD/beta thal; $50M contingent upfront plus annual fees.

## SEC filing metadata
- accession: 0001650664-24-000006
- form_type: 8-K
- ticker: EDIT
- cik: 0001650664
- company_name: Editas Medicine, Inc.
- filed_at: 2024-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650664/000165066424000006/0001650664-24-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650664/000165066424000006/edit-20240228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001650664-24-000006
- JSON: https://secwatch.observer/filing/0001650664-24-000006.json
- Plain text: https://secwatch.observer/filing/0001650664-24-000006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.